News

Xeljanz, claimed to be the first and only Janus kinase (JAK) inhibitor approved in the US to treat pcJIA, is available in two formulations such as a tablet

The company’s investigational new drug application (IND) for the clinical trial will be on partial clinical hold until the regulator receives satisfying answers for the questions. The partial

RA is a chronic, progressive, systemic, inflammatory disease that can lead to significant and irreversible joint destruction, pain and functional impairment.2 Almost 3 million people in Europe are

ELEVATE UC 12 is the second of two pivotal trials within the Phase 3 ELEVATE UC registrational program to assess the safety and efficacy of etrasimod 2 mg.

Nucala has been approved to treat adult and paediatric patients aged 12 years and older with HES ≥ six months without an identifiable non-haematologic secondary cause. Mepolizumab, the

The scope of the deal comprises technical transfer, and fill and finish manufacture of J&J’s SARS-CoV-2 vaccine candidate. GRAM stated that it is having modern equipment to manufacture

“We are pleased to advance MLE-301 into clinical development, prioritizing our resources on this valuable asset and leveraging Millendo’s expertise in the NK3R category,” said Julia C. Owens,

Anokion plans to initiate a multi-center, Phase 1 clinical trial of ANK-700 in people with MS by the end of this year. “Multiple sclerosis remains a devastating disease

The trial’s top-line data from 203 participants demonstrate that severe or critical Covid-19 patients treated with SACCOVID witnessed speedy recovery and a significant reduction in disease progression to